Ind-Swift Labs Q1 PAT jumps 3x to Rs 24.4 Cr; revenue up 21% YoY, sells land for Rs 17.5 Cr
INDSWFTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 19.3 pts more than Nifty Microcap 250 and 19.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Q1 FY27 standalone revenue from operations rose 21% YoY to Rs 186.08 Cr. Net profit tripled to Rs 24.44 Cr from Rs 8.12 Cr. EBITDA surged to Rs 33.32 Cr vs Rs 8.44 Cr. Consolidated net profit at Rs 24.68 Cr. Board also approved sale of 10-acre Punjab land for Rs 17.50 Cr over 9 months, land found unsuitable for pharma facility. Auditor review unqualified.
Strong earnings beat with 3x PAT growth and EBITDA expansion signals operational turnaround. Land sale adds Rs 17.5 Cr cash inflow.